Overview

Thank you to all the delegates who attended the FT Global Pharmaceutical & Biotechnology Conference 2011, Europe's pre-eminent industry event attended by over 300 delegates over 2 insightful days of discussion between leading industry executives, government decision makers, investors, analysts and other specialist providers.

      Delegate LinkedIn group  
      Follow us on Twitter #ftpharma  
 


CONFERENCE CHAIRED BY:


 Andrew Jack
 Pharmaceuticals Correspondent
 Financial Times		    Bob Go
 Vice Chairman
 Deloitte LLP

 
CONFIRMED SPEAKERS INCLUDED:

  • The Rt Hon David Cameron MP, Prime Minister of the United Kingdom
  • The Rt Hon David Willetts MP, Minister of State for Universities & Science
  • Sir David Nicholson KCB CBE, CEO, National Health Service
  • Dame Sally Davies DBE, Director of Research and Development and Chief Scientific Adviser for the Department of Health and National Health Service
  • Miles D White, Chairman of the Board and CEO, Abbott
  • Dr Severin Schwan, CEO, Roche Group
  • Alex Gorsky, Vice Chairman, Executive Committee, Johnson & Johnson
  • Dr Jörg Reinhardt, Chairman of the Board of Management, Bayer HealthCare AG
  • Lars Rebien Sørensen, President and CEO, Novo Nordisk A/S
  • The Rt Hon Andrew Lansley MP, Secretary of State for Health, UK Government
  • Professor Sir Kent Woods, Chief Executive, Medicines and Healthcare products Regulatory Agency and Chairman of the Management Board, European Medicines Agency
  • Dr Margaret A. Hamburg, Commissioner, U.S. Food and Drugs Administration
  • Dr Mehmood Khan, CEO, Global Nutrition Group and Chief Scientific Officer, PepsiCo
  • Dr Samantha Du, Founder and Former CEO, Hutchison MediPharma Ltd
  • David Redfern, Chief Strategy Officer, GlaxoSmithKline
  • Michael Rosenblatt, MD, Chief Medical Officer and EVP, Merck
  • Brent Saunders, CEO, Bausch + Lomb
  • Rajiv Gulati, President - Global Pharmaceutical Business, Ranbaxy Laboratories Ltd
  • Tony Zook, EVP Global Commercial, AstraZeneca
  • Dr John Pottage,Chief Scientific and Medical Officer, ViiV Healthcare
  • Neil de Crescenzo, SVP and General Manager Health Sciences Global Business Unit, Oracle Corporation
       


Issues addressed included:

  • Incentivising and rewarding innovation: what innovation is worth paying for?
  • Emerging markets: transforming the life science business model for the needs of emerging markets
  • Pharma and consumer businesses -healthy convergence or awkward partners?
  • R&D: new financing and business models for innovation
  • Strategy forum: how is the nature of competition in the life sciences industry changing? What will the pharma company of the future look like?